Home > Blog > Advancing dose escalation strategies with bayesian modeling

1 min read

Advancing Dose Escalation Strategies with Bayesian Modeling

Oncology

Learn how our biostatistics and strategic consulting teams collaborated with our biotechnology sponsor to advance dose escalation strategies through Bayesian modeling in a Phase 1/2 study for a novel oncology compound. Our efforts led to real-time, data-driven decision making and reduced trial duration while maintaining patient safety.

A biotechnology sponsor developing an oncology therapy engaged us to support the design and execution of a multicenter, open-label Phase 1/2 dose escalation and expansion study. The sponsor aimed to shorten traditional dose escalation timelines without compromising patient safety, moving beyond conventional 3+3 design limitations.

In this case study, learn how Veristat experts were able to work with the sponsor to solve challenges across:

  • Bayesian CRM implementation

  • Real-time decision support

  • Operational complexity management

  • Safety review committee participation

  • Multi-cycle DLT integration

  • Strategic consultative planning

Download our complete case study "Advancing Dose Escalation Strategies with Bayesian Modeling"

DOWNLOAD

 
Contact us today to learn how we can help:
LET'S TALK

2 min read

Meet Veristat at BIOSPAIN 2026

Oct 5, 2026  Veristat Events

Where Biotech Innovation Meets the Path Forward

BIOSPAIN 2026: September 29- October 1, 2026 – Bilbao, Spain

Veristat...

2 min read

Meet Veristat at SCOPE Europe 2026

Oct 5, 2026  Veristat Events

Where Clinical Trial Strategy Meets Smarter Execution

SCOPE Europe: October 13-14, 2026 – Barcelona, Spain

Veristat is...